ARS Pharmaceuticals Stock (NASDAQ:SPRY)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$4.32

52W Range

$3.81 - $13.15

50D Avg

$4.81

200D Avg

$7.59

Market Cap

$400.77M

Avg Vol (3M)

$1.71M

Beta

0.88

Div Yield

-

SPRY Company Profile

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

195

IPO Date

Dec 04, 2020

Website

SPRY Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Product	$72.19M	$7.25M

Fiscal year ends in Dec 25 | Currency in USD

SPRY Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$84.28M	$89.15M	$30.00K
Operating Income	$-179.45M	$-3.08M	$-67.52M
Net Income	$-171.30M	$8.00M	$-54.37M
EBITDA	$-179.45M	$-3.00M	$-67.45M
Basic EPS	$-1.74	$0.08	$-0.57
Diluted EPS	$-1.74	$0.08	$-0.57

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 13, 26 | 4:30 PM

Q1 26May 15, 26 | 8:30 AM

Q4 25Mar 09, 26 | 8:30 AM

Peer Comparison

Ticker	Company
AQST	Aquestive Therapeutics, Inc.
MNKD	MannKind Corporation
XERS	Xeris Biopharma Holdings, Inc.